Mirae Asset Global Investments Co. Ltd. Increases Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Mirae Asset Global Investments Co. Ltd. increased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 47.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,684 shares of the medical equipment provider’s stock after buying an additional 3,772 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Lantheus were worth $1,041,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Wilmington Savings Fund Society FSB acquired a new position in Lantheus during the third quarter worth about $25,000. Signaturefd LLC increased its stake in shares of Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 92 shares in the last quarter. UMB Bank n.a. lifted its stake in Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after buying an additional 126 shares in the last quarter. GAMMA Investing LLC grew its holdings in Lantheus by 45.5% during the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after buying an additional 146 shares during the last quarter. Finally, World Investment Advisors LLC purchased a new position in Lantheus during the third quarter worth $60,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on LNTH. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. The Goldman Sachs Group initiated coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price on the stock. JMP Securities reiterated a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. Finally, Truist Financial reissued a “buy” rating and issued a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $131.86.

Lantheus Stock Performance

Shares of LNTH stock opened at $81.92 on Wednesday. The firm has a market capitalization of $5.70 billion, a price-to-earnings ratio of 13.63 and a beta of 0.44. Lantheus Holdings, Inc. has a one year low of $54.69 and a one year high of $126.89. The company has a 50 day moving average price of $91.89 and a 200 day moving average price of $98.24.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.